Pasar al contenido principal

EXPLORANDO NUEVAS ESTRATEGIAS EN ENFERMEDADES VIRICAS Y TUBERCULOSIS: PLASTICIDAD CONFORMACIONAL, RESISTENCIA A MUTACIONES Y MODIFICACION QUIMICA PSEUDOIRREVERSIBLE

PID2020-117646RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Multicomponent Reaction-Based Platform Opens New Avenues in Aryl Hydrocarbon Receptor Modulation

  • Nadal Rodríguez, Pau
  • Hartung, Frederick
  • Pedrola, Marina
  • Coomar, Seemon
  • Diaz Moreno, Alejandro
  • Hätälä, Anna M.
  • Rolfes, Katharina M.
  • Sánchez Vera, Ismael
  • Gil, Joan
  • Molins, Elies
  • Viayna, Antonio
  • Hanzl, Alexander
  • Thomä, Nicolas H.
  • Haarmann-Stemmann, Thomas
  • Luque, F. Javier
  • Lavilla, Rodolfo
  • Ghashghaei, Ouldouz
A multidisciplinary platform is presented to address aryl hydrocarbon receptor (AhR) modulation. A rewired Yonemitsu multicomponent reaction with indole 2-carboxaldehydes and nucleophilic species was designed to access a family of 6-substituted indolocarbazoles. The conformational behavior of these compounds was examined to rationalize their axial chirality. In silico docking and molecular simulations highlighted key features implicated in their binding to AhR. Furthermore, the synthesis of linkable derivatives allowed the direct development of conjugated entities. Reporter gene and target gene expression analyses identified these novel structures as potent noncytotoxic activating AhR ligands, that can be extended to bifunctional molecules. The anti-inflammatory properties of these AhR agonists were assessed in interleukin-13 treated keratinocytes. Altogether, the synergistic research in synthetic and computational chemistry integrated with biological studies opens novel avenues toward understanding the biological roles of AhR and the development of targeted therapeutics., We thank Profs. G. Fabriàs, I. Alfonso, Dr. D. Carbajo (IQAC, CSIC Barcelona, Spain), Prof. V. Marchán and Drs. M. A. Molins and A. Gallen (U. Barcelona), Profs. D. Peña and D. Pérez (U. Santiago de Compostela) for useful suggestions and support. We acknowledge the funding from the Ministerio de Ciencia e Innovación-Spain and European Regional Development Fund (EDFR) (PID2022-139180OB-I00, PID2020-117646RB-I00 AEI/10.13039/501100011033, PID2020-120537RB-I00, PID2021-124572OB-C32), Ministerio de Economía y Competitividad-Spain (CEX2021-001202-M), the State Investigation Agency through the Severo Ochoa Programme for Centres of Excellence in R&D (CEX2023-001263-S), Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition Project) and the Generalitat de Catalunya (2021SGR00357, 2021SGR00671). T.H.-S. acknowledges the support by the German Research Foundation (DFG) FOR 5489 (HA 7346/6-1). P.N.R. thanks Ministerio de Ciencia e Innovación (Spain) for a predoctoral grant. F.H. was supported by the Jürgen Manchot Foundation. N.H.T. acknowledges the support by the European Research Council (ERC) under the European Union’s Horizon 2020 research program (NucEM, No. 884331), the Novartis Research Foundation, the Swiss National Science Foundation (310030_301206 and 310030_214852) and Krebsforschung Schweiz (KFS-5933-08-2023). A.H. is supported by the SNSF Swiss Postdoctoral Fellowship (TMPFP3_224735). The authors acknowledge BioRender.com for assistance with figure creation. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) license to any accepted manuscript version arising., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Influenza A virus hemagglutinin: from classical fusion inhibitors to proteolysis targeting chimera-based strategies in antiviral drug discovery

  • Hermoso-Pinilla, Francisco Javier
  • Valdivia, Aitor
  • Camarasa Rius, María José
  • Ginex, Tiziana
  • Luque, Francisco Javier
The influenza virus glycoprotein hemagglutinin (HA) participates in critical steps of the attachment of viral particles to the host cell membrane receptor and membrane fusion. Due to its crucial involvement in the initial phases of influenza A infections, HA emerges as a promising target in the search of novel drug-like candidates. Given its pivotal role in the early stages of influenza A infections, intense drug discovery efforts have been undertaken to target HA in the past decades. Drug discovery studies mainly rely on preventing the recognition of sialic acid units by the receptor binding site in the globular head (GH) domain, or the conformational rearrangement required for the fusion of viral and cell membranes. In this work, the aim is to summarize the progress made in HA-targeted development of small molecule fusion inhibitors. To this end, attention will primarily be focused on the analysis of the X-ray crystallographic structures of HA bound to fusion inhibitors. Furthermore, this study also aims to highlight the efforts made in exploiting the structural information in conjunction with molecular modeling techniques to discern the mechanism of action of the fusion inhibitors and to assist the design and interpretation of structure-activity relationships of novel lead compounds will be highlighted. The final section will be dedicated to elucidating novel and promising antiviral strategies proceeding from the transformation of known small molecule antivirals in proteolysis targeting chimera (PROTAC)-based targeted protein degradation. This knowledge will be valuable to assist the exploitation of classical and novel antiviral structure-based strategies, together with a deeper understanding of the mechanism of action and minimization of the impact of drug resistance., The research was given financial support by the Spanish Ministerio de Ciencia e Innovación [PID2020117646RB-I00 MCIN/AEI/10.13039/501100011033, PID2019-104070-RB-C21]; the Spanish Ministerio de Ciencia, Innovación y Universidades [PID2022-136307OB-C21/AEI/10.13039/501100011033/FEDER, UE]; Maria de Maetzu [CEX2021-001202-M]; Generalitat de Catalunya [2021SGR00671]; and Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC) [CSIC-PIE201980E100, CSICPIE201980E028, CSIC-PIE202380E095]. FJH has fellowship from the Spanish Ministerio de Ciencia e Innovación [PRE2021-100418]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed